TFC News
2025-2026 Board of Directors
The Thyroid Foundation of Canada is pleased to announce the 2025-2026 Board of Directors. The nominees were elected at the Annual General Meeting.
Health Canada Approves Tepezza
Health Canada approved the tepro-tumumab (Tepezza) drug for thyroid eye disease on April 17, 2025. Tepezza “reduces eye bulging and double vision…”
Regulatory Review of New TED Drug
TFC is supporting the Canadian regulatory review of the teprotumumab (Tepezza) drug for treating Thyroid Eye Disease produced by Amgen …
Thyroid Cancer Survivors Survey
A team of clinical researchers at the University of Calgary and thyroid cancer survivors are looking into thyroid cancer patient experiences, treatment satisfaction, and opportunities to…
New RFA Facility in Halifax
A new Radio Frequency Ablation (RFA) facility for thyroid nodules is now available at the Nova Scotia Health Authority, Bayers Lake Community Outpatient Centre, Halifax NS.
Thyroid Eye Disease Survey
We are conducting an important survey on the impact of thyroid eye disease (TED) on patients and caregivers.
The survey has now been completed.
